All In Biotech

Drug Trial Radar · NCT02314819

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Last checked: Nov 19, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Dec 2014

Primary completion

Jan 2017

Study completion Jan 17, 2017

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
Collaborators
Fudan University; Eighty-One Hospital of People's Liberation Army
First posted
Dec 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fruquintinib administered at 5mg once daily(QD) in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with metastatic colorectal cancer (CRC) in phase Ib and phase 2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of patients with metastatic CRC who have progressed after second line or above standard chemotherapy

Conditions

  • Colorectal Cancer

Interventions

  • fruquintinibDrug

    fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

  • placeboDrug

    fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. overall survivalTime frame: from randomization until death due to any cause, assessed up to 2 year

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Hutchison Medi Pharma Investigational Site

    Hefei, Anhui, China

  • Hutchison Medi pharma Investigational Site

    Beijing, Beijing Municipality, China

  • Hutchison Medi Pharma Investigational Site

    Guangzhou, Guangdong, China

  • Hutchison Medi Pharma investigational site

    Shenzhen, Guangdong, China

  • Hutchison Medi Pharma Investigational Site

    Liuzhou, Guangxi, China

  • Hutchison Medi Pharma Investigational Site

    Harbin, Heilongjiang, China

  • Hutchison Medi Pharma Investigational Site

    Changsha, Hunan, China

  • Hutchison Medi Pharma Investigational Site

    Changzhou, Jiangsu, China

  • Hutchison Medi Pharma Investigational Site

    Nanjing, Jiangsu, China

  • Hutchison Medi Pharma Investigational Site

    Nantong, Jiangsu, China

  • Hutchison Medi Pharma Investigational Site

    Xuzhou, Jiangsu, China

  • Hutchison Medi Pharma Investigational Site

    Changchun, Jilin, China

  • Hutchison Medi Pharma Investigational Site

    Qingdao, Shandong, China

  • Hutchison Medi Pharma Investigational Site

    Shanghai, Shanghai Municipality, China

  • Hutchison Medi Pharma Investigational Site

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.